Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Overview of attention for article published in Breast Cancer Research, April 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

patent: 2 patents

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 35 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

Methods and devices for predicting anthracycline treatment efficacy

Grant US-11214836-B2

United States of America

METHODS AND DEVICES FOR PREDICTING ANTHRACYCLINE TREATMENT EFFICACY

Application WO-2016008048-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.